Evoke Pharma Inc. (NASDAQ:EVOK) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $7.32 and last traded at $7.30, with a volume of 71,877 shares traded. The stock had previously closed at $6.51.

EVOK has been the topic of several recent analyst reports. Brean Capital reiterated a “buy” rating and issued a $13.00 target price on shares of Evoke Pharma in a report on Friday, March 11th. Ascendiant Capital Markets lifted their target price on shares of Evoke Pharma from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, March 14th. Rodman & Renshaw reiterated a “buy” rating and issued a $27.00 target price on shares of Evoke Pharma in a report on Monday, March 14th. FBR & Co reiterated an “outperform” rating and issued a $17.00 target price on shares of Evoke Pharma in a report on Tuesday, March 15th. Finally, Northland Securities initiated coverage on shares of Evoke Pharma in a report on Wednesday, March 16th. They issued an “outperform” rating and a $16.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Evoke Pharma currently has a consensus rating of “Buy” and an average target price of $17.47.

The firm’s 50 day moving average price is $6.04 and its 200-day moving average price is $4.56. The firm’s market cap is $60.67 million.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities analysts expect that Evoke Pharma Inc. will post ($1.37) EPS for the current year.

In related news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the stock in a transaction on Thursday, May 26th. The shares were sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of the stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $5.07, for a total transaction of $25,831.65. The disclosure for this sale can be found here.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.